Skip to content
SPACListing
SearchingNasdaq

Frazier Life Sciences Acquisition Corp. IIFLSC

Class A FLSCCIK 0002153598

Cash in trust

—

Not yet disclosed

Trust per share

—

Redemption value

IPO

Oct 2026

—

Combination deadline

—

Not disclosed

Filings on record

21

Latest Oct 23, 2026

Overview

Frazier Life Sciences Acquisition Corp. II is a special purpose acquisition company incorporated in Cayman Islands and registered with the SEC under CIK 0002153598. It completed its initial public offering in Oct 2026 and listing on Nasdaq. Class A shares trade under the ticker FLSC on Nasdaq. IPO closed, trust funded, no definitive agreement announced.

Scores

Recomputed 5h ago

Three readings of Frazier Life Sciences Acquisition Corp. II, each an unweighted mean of the components shown beneath it, and each component a percentile against every live SPAC rather than an absolute we invented. They describe the setup, not the merit. How they are built

FOMO

High

How much attention is this vehicle attracting right now?

79/100

  • Filing activity99

    20 in 30 days

  • News coverage88

    4 stories in 30 days

  • News tone50

    neutral

Attention is not quality. FOMO rises on news volume and on the market paying above trust, both of which have preceded plenty of disappointments.

These are derived measures, not ratings of investment merit. They carry no view on the target, no price target and no recommendation, and a high score is not a reason to buy anything.

News on Frazier Life Sciences Acquisition Corp. II

Last 90 days

News sentiment

Neutral
negativeneutralpositive

Across 1 recent story, weighted towards the newest. Scored by our own headline classifier using finance- and SPAC-specific terms. It reads what a story is about, not what the shares are worth.

SEC filing history

Free tier: filings older than 24 hours
  • 8-K

    Other events

    Items 8.01, 9.01 · Accession 0001193125-26-429129

    Oct 23, 2026

    1d ago

    View on EDGAR ↗
  • SCHEDULE 13G

    Beneficial ownership report (passive)

    Accession 0001346824-26-000245

    Oct 23, 2026

    1d ago

    View on EDGAR ↗
  • SCHEDULE 13D

    Beneficial ownership report (activist)

    Accession 0001193125-26-428005

    Oct 22, 2026

    2d ago

    View on EDGAR ↗
  • SCHEDULE 13G

    Beneficial ownership report (passive)

    Accession 0000921895-26-002836

    Oct 22, 2026

    2d ago

    View on EDGAR ↗
  • SCHEDULE 13G

    Beneficial ownership report (passive)

    Accession 0001172661-26-004630

    Oct 22, 2026

    2d ago

    View on EDGAR ↗
  • SCHEDULE 13G

    Beneficial ownership report (passive)

    Accession 0001104659-26-116496

    Oct 16, 2026

    7d ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001193125-26-422957

    Oct 16, 2026

    8d ago

    View on EDGAR ↗
  • 8-K

    Entry into a material definitive agreement; Other events

    Items 1.01, 3.02, 5.03, 8.01, 9.01 · Accession 0001193125-26-422919

    Oct 16, 2026

    8d ago

    View on EDGAR ↗
  • 424B4

    Final IPO prospectus

    Accession 0001193125-26-421735

    Oct 15, 2026

    9d ago

    View on EDGAR ↗
  • EFFECT

    Notice of effectiveness

    Accession 9999999995-26-003227

    Oct 14, 2026

    9d ago

    View on EDGAR ↗
  • 3

    Initial statement of beneficial ownership

    Accession 0001193125-26-420812

    Oct 14, 2026

    10d ago

    View on EDGAR ↗
  • 3

    Initial statement of beneficial ownership

    Accession 0001193125-26-420801

    Oct 14, 2026

    10d ago

    View on EDGAR ↗
  • 3

    Initial statement of beneficial ownership

    Accession 0001193125-26-420796

    Oct 14, 2026

    10d ago

    View on EDGAR ↗
  • 3

    Initial statement of beneficial ownership

    Accession 0001193125-26-420791

    Oct 14, 2026

    10d ago

    View on EDGAR ↗
  • 3

    Initial statement of beneficial ownership

    Accession 0001193125-26-420790

    Oct 14, 2026

    10d ago

    View on EDGAR ↗
  • 3

    Initial statement of beneficial ownership

    Accession 0001193125-26-420789

    Oct 14, 2026

    10d ago

    View on EDGAR ↗
  • 3

    Initial statement of beneficial ownership

    Accession 0001193125-26-420782

    Oct 14, 2026

    10d ago

    View on EDGAR ↗
  • CERT

    Exchange listing certification

    Accession 0001354457-26-000983

    Oct 13, 2026

    10d ago

    View on EDGAR ↗
  • 8-A12B

    Registration of securities on an exchange

    Accession 0001193125-26-417909

    Oct 9, 2026

    15d ago

    View on EDGAR ↗
  • S-1

    Registration statement for the initial public offering

    Accession 0001193125-26-399703

    Sep 24, 2026

    1mo ago

    View on EDGAR ↗
  • DRS

    Draft registration statement (confidential)

    Accession 0001193125-26-389015

    Sep 11, 2026

    1mo ago

    View on EDGAR ↗

Pro

Track FLSC without the delay

Free accounts see this filing history a day late. Pro shows every document minutes after EDGAR publishes it, opens it on EDGAR in one click, and adds the twelve-month deadline calendar.

  • Filings live, no 24-hour delay
  • One click through to the source document
  • Deadline calendar out to 12 months
  • CSV export, API and MCP access

Cancel any time. Billed monthly in USD.

Frazier Life Sciences Acquisition Corp. II: questions answered

What is Frazier Life Sciences Acquisition Corp. II (FLSC)?

Frazier Life Sciences Acquisition Corp. II is a special purpose acquisition company incorporated in Cayman Islands and registered with the SEC under CIK 0002153598. It completed its initial public offering in Oct 2026 and listing on Nasdaq. Class A shares trade under the ticker FLSC on Nasdaq. IPO closed, trust funded, no definitive agreement announced.

How much does Frazier Life Sciences Acquisition Corp. II hold in trust?

No trust balance has been disclosed in a filing we have indexed for Frazier Life Sciences Acquisition Corp. II. For a newly priced IPO this is normal: the figure first appears in the quarterly report after closing.

When must Frazier Life Sciences Acquisition Corp. II complete a merger?

No combination deadline appears in the filings we have indexed. The date is stated in the charter and repeated in each quarterly report; where our parser could not establish it with confidence we leave it blank rather than infer one.

What happens if Frazier Life Sciences Acquisition Corp. II does not find a target in time?

The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.

Can I redeem shares in Frazier Life Sciences Acquisition Corp. II, and at what price?

Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.

What tickers does Frazier Life Sciences Acquisition Corp. II trade under?

Class A shares trade as FLSC on Nasdaq. Units trade first and separate into their component securities roughly 52 days after the IPO; only the Class A shares carry the redemption right against the trust.

Is the trust value the same as the share price for Frazier Life Sciences Acquisition Corp. II?

No. Trust per share is a disclosed, contractual figure: what a redeeming holder receives. The market price is whatever the shares change hands at, which can sit above the trust when a deal is well received or below it when the market doubts one will close. We do not have a current quote for this vehicle, so no spread is shown.

Is Frazier Life Sciences Acquisition Corp. II tradeable, and where?

Yes. FLSC returned a live quote of $10.30 on Nasdaq. Quotes here are delayed and refreshed on a schedule rather than streamed, so treat the figure as indicative and confirm on your own venue. Units and warrants trade under their own symbols and are quoted separately.

Is Frazier Life Sciences Acquisition Corp. II a good investment?

That is not a question this site answers. Frazier Life Sciences Acquisition Corp. II is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.

Where does this Frazier Life Sciences Acquisition Corp. II data come from?

Filings Frazier Life Sciences Acquisition Corp. II submitted to the SEC under CIK 0002153598: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.

Compiled by the SPACListing research desk

Last reconciled Oct 24, 2026

Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.

Read the full methodology · What is in the dataset · Report a correction

SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.

Continue reading

The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.